indiaUpdated: Jul 18, 2020 09:48 ISTBharat Biotech International Limited (BBIL), which developed India’s first potential indigenous coronavirus disease (Covid-19) vaccine, has said the first phase of testing has begun on 375 people, according to a report on Saturday. Hindustan, HT’s sister publication, reported that Bharat Biotech has said that human trials of Covaxin started on July 15. The Hyderabad-based pharmaceutical company has jointly developed the vaccine with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). During the first phase of the trial, it is checked whether the people who have been vaccinated develop any adverse effect in their body. It was the first to get the regulatory nod to begin phase 1 and phase 2 human trials to test the vaccine for efficacy and safety.

Source: Hindustan Times July 18, 2020 03:44 UTC